BICYCLE THERAPEUTICS PLC-ADR (BCYC)

Company Profile

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 236 full-time employees. The company went IPO on 2019-05-23. The firm is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The firm is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Company Info

BICYCLE THERAPEUTICS PLC-ADR

Blocks A & B, Portway Building, Granta Park, Great Abington

Cambridge CAMBRIDGESHIRE CB22 3AT

P: 11441223261503

CEO: Kevin Lee

Employees: 236

Website: https://www.bicycletherapeutics.com/